Cialis
Product Images NDC 50436-4465

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Cialis (NDC 50436-4465). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Services, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Cialis Uspi F001 Structure V1)

Chemical structure of the active ingredient in Cialis, showing the molecular arrangement with rings and functional groups typical of tadalafil.*

FDA Label Image

Figure (Cialis Uspi F001 V2)

A line graph depicting plasma tadalafil concentration (µg/L) over time (hours) for Cialis. It shows concentration profiles for three dosing regimens: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose following 5 consecutive days of administration. Error bars indicate variability at each time point.*

FDA Label Image

Figure (Cialis Uspi F002 V1)

A set of four line graphs showing the difference in blood pressure (BP) measurements between tadalafil and placebo over time in hours. The graphs display standing systolic BP, standing diastolic BP, supine systolic BP, and supine diastolic BP, with error bars indicating variability around the mean difference values.*

FDA Label Image

Figure (Cialis Uspi F003 V1)

This image contains two line graphs comparing standing and supine systolic blood pressure (BP) in mmHg over a 24-hour period post-dose. The graphs compare measurements for two groups: one receiving Tadalafil 20 mg with doxazosin 8 mg and the other receiving placebo with doxazosin 8 mg. The X-axis represents time in hours post-dose, and the Y-axis represents change in systolic BP.*

FDA Label Image

Figure (Cialis Uspi F004 V1)

A line graph showing the effect of 20 mg tadalafil combined with 8 mg doxazosin versus placebo with 8 mg doxazosin on systolic blood pressure (mmHg) over 12 hours after administration. The graph includes data for morning (08:00) and evening (20:00) dosing times, with systolic BP changes plotted against time.*

FDA Label Image

Figure 5 (Cialis Uspi F005 V1)

Line graph comparing the change from baseline in IPSS total score over 12 weeks of treatment for Cialis 5 mg and placebo. The x-axis represents the duration of treatment in weeks (0, 4, 8, 12), and the y-axis shows the change from baseline with negative values indicating a decrease in score. The Cialis 5 mg group shows a greater reduction in IPSS score over time compared to placebo, with statistical significance indicated at week 12 (p<0.01).*

FDA Label Image

Figure 6 (Cialis Uspi F006 V1)

A line graph showing the change from baseline in IPSS total score over 12 weeks of treatment comparing Cialis 5 mg and placebo. The y-axis represents the change in IPSS total score, and the x-axis shows treatment duration in weeks. Cialis 5 mg shows a greater reduction in IPSS score than placebo, with statistically significant differences at multiple time points (p<0.01).*

FDA Label Image

Figure 7 (Cialis Uspi F007 V2)

A line graph depicting weeks of therapy on the x-axis and least squares mean change from baseline on the y-axis. It compares Tadalafil/Finasteride with Placebo/Finasteride over 26 weeks, showing data points at weeks 0, 4, 12, and 26. The graph includes statistical significance markers with p-values less than 0.001 and 0.05.*

FDA Label Image

Figure 8 (Cialis Uspi F008 V1)

A line graph comparing the change from baseline in IPSS total score over 12 weeks of treatment between Cialis 5 mg and placebo groups. The x-axis represents treatment duration in weeks, and the y-axis shows change in IPSS score. Cialis 5 mg shows a greater reduction in score over time compared to placebo.*

FDA Label Image

Label Image (Lbl504364462)

Cialis 5 mg tablets packaging label from Unit Dose Services. The label shows the proprietary name, active ingredient tadalafil strength of 5 mg, and specifies one tablet per unit dose pouch with 200 pouches per case. It includes storage instructions to keep between 25°C (77°F) and keep away from children, as well as manufacturing and repackaging information involving Eli Lilly and Company, Lilly USA LLC, and Unit Dose Services. Contact information is provided for questions or comments.*

FDA Label Image

Label Image (Lbl504364463)

Cialis 10 mg tablet label showing active ingredient tadalafil. The label includes dosage instructions cautioning tablets should not be split and the entire dose should be taken. Manufactured by Lilly USA LLC, Indianapolis, IN and packaged by Unit Dose Services, LLC, Dania, FL. The label also displays NDC 50436-4463-1 and typical batch and expiration placeholders.*

FDA Label Image

Label Image (Lbl504364464)

Cialis 20 mg tablet packaging label, containing tadalafil. Label includes dosing instructions stating tablets should not be split and entire dose should be taken. Manufactured by Lilly USA LLC, Indianapolis, IN, with NDC 50436-4464-1. Label indicates the product is RX only and advises storing at 25°C and keeping out of reach of children.*

FDA Label Image

Label Image (Lbl504364465)

Cialis (Tadalafil) 2.5 mg blister pack label containing 30 tablets, labeled for once daily use. Manufactured by Lilly USA LLC, Indianapolis, IN, and packaged by Unit Dose Services, LLC, Dania, FL. The label includes dosage strength, quantity, storage instructions, and a warning to keep out of reach of children. It features the NDC number 50436-4465-1 and barcodes.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.